StockNews.AI
TCBP
StockNews.AI
187 days

TCBP Announces Successful Completion of Cohort A in the ACHIEVE Clinical Trial

1. TC BioPharm reports favorable safety in TCB008 trial for relapsed AML. 2. No adverse events reported; suggests promising efficacy in patients.

2m saved
Insight
Article

FAQ

Why Bullish?

Positive trial results can attract investors. Similar past announcements boosted stock prices.

How important is it?

Clinical trial results are critical for biotech; implications on commercial viability are significant.

Why Long Term?

Positive data may lead to greater market interest over time. Repeated efficacy could establish credibility.

Related Companies

TCBP
No adverse events related to TCB008 have occurred Evidence of stable disease following TCB008 infusion EDINBURGH, Scotland , Feb. 13, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that it has concluded dosing of Cohort A patients in the ACHIEVE Phase 2B UK clinical trial. The available data show a favorable safety and efficacy response in Cohort A patients, patients with relapse or refractory AML.

Related News